Mutation associations in RA-defiant APL

Abstract

One-quarter of acute promyelocytic leukemia (APL) patients develop resistance to all-trans retinoic acid (ATRA)/chemotherapy (CT). In this issue of Blood, Gallagher et al report the associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities (ACAs) in relapsed APL.